- Home
- BILI vs REVBW Comparison
BILI vs REVBW Comparison
Compare BILI & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BILI
- REVBW
- Stock Information
- Founded
- BILI 2009
- REVBW N/A
- Country
- BILI China
- REVBW United States
- Employees
- BILI N/A
- REVBW 9
- Industry
- BILI EDP Services
- REVBW Biotechnology: Pharmaceutical Preparations
- Sector
- BILI Technology
- REVBW Health Care
- Exchange
- BILI Nasdaq
- REVBW Nasdaq
- Market Cap
- BILI N/A
- REVBW N/A
- IPO Year
- BILI 2018
- REVBW 2020
- Fundamental
- Price
- BILI $16.21
- REVBW $0.02
- Analyst Decision
- BILI Strong Buy
- REVBW
- Analyst Count
- BILI 9
- REVBW 0
- Target Price
- BILI $20.59
- REVBW N/A
- AVG Volume (30 Days)
- BILI 5.5M
- REVBW N/A
- Earning Date
- BILI 05-22-2025
- REVBW N/A
- Dividend Yield
- BILI N/A
- REVBW N/A
- EPS Growth
- BILI N/A
- REVBW N/A
- EPS
- BILI N/A
- REVBW N/A
- Revenue
- BILI $3,676,004,571.00
- REVBW N/A
- Revenue This Year
- BILI $15.36
- REVBW N/A
- Revenue Next Year
- BILI $8.96
- REVBW N/A
- P/E Ratio
- BILI N/A
- REVBW N/A
- Revenue Growth
- BILI 19.10
- REVBW N/A
- 52 Week Low
- BILI $10.84
- REVBW N/A
- 52 Week High
- BILI $31.77
- REVBW N/A
- Technical
- Relative Strength Index (RSI)
- BILI 38.15
- REVBW N/A
- Support Level
- BILI $15.87
- REVBW N/A
- Resistance Level
- BILI $17.50
- REVBW N/A
- Average True Range (ATR)
- BILI 0.93
- REVBW 0.00
- MACD
- BILI -0.09
- REVBW 0.00
- Stochastic Oscillator
- BILI 35.05
- REVBW 0.00
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).